Related Experiment Videos
Insulin therapy in maturity-onset diabetes
T Sane1, P Mustajoki, M Välimäki
1Third Department of Medicine, University Central Hospital, Helsinki, Finland.
Annals of Medicine
|February 1, 1991
Summary
Insulin therapy is recommended for maturity onset diabetes patients unresponsive to oral medications, improving glycemic control and well-being. Long-term benefits on health outcomes require further study, but insulin remains a viable treatment option.
Area of Science:
- Endocrinology
- Metabolic Diseases
Background:
- Insulin's primary role in maturity onset diabetes is suppressing hepatic glucose production.
- Oral medications are standard, but some patients require insulin for glycemic control.
Purpose of the Study:
- To review the role and regimens of insulin therapy in maturity onset diabetes.
- To assess the benefits and drawbacks of insulin treatment in this patient population.
Main Methods:
- Review of current literature on insulin therapy for maturity onset diabetes.
- Discussion of established and alternative insulin regimens.
- Analysis of potential benefits (glycemic control, lipid profile) and risks (hypoglycemia, weight gain).
Main Results:
- Insulin improves glycemic control, lipid profiles, and well-being in non-responsive patients.
- Long-term effects on morbidity and mortality are unproven; regimens are not fully established.
- Hypoglycemia is uncommon, but moderate weight gain is typical; atherogenesis link is unresolved.
Conclusions:
- Insulin therapy is indicated for maturity onset diabetes patients failing oral agents.
- Treatment should be individualized, starting with simpler regimens and escalating if needed.
- Further research is needed to confirm long-term benefits and optimize therapeutic strategies.